Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ULK4 pseudogene 2 (ULK4P2), also reported as "D-X", is annotated as a pseudogene related to the ULK4 (Unc-51-like kinase 4) gene, which means it does not encode a functional protein product. ULK4 itself is a pseudokinase involved in neurodevelopment and neuropsychiatric disorders[1][3]. However, a pseudogene like ULK4P2 typically does not have known molecular functions, disease relevance, or therapeutic targeting potential. There is no evidence that ULK4P2 encodes an active protein, participates in any recognized biological pathway, or is considered a drug target. There is also no data supporting its use as a biomarker, its association with disease, or any involvement with approved or investigational drugs. ULK4P2 is not considered a typical therapeutic target such as a receptor, enzyme, or transporter; it may be misidentified as such. Note: Most published research and data concerns the parent gene ULK4, not the pseudogene ULK4P2. If your focus is on ULK4 itself, detailed information exists regarding its roles in neurodevelopment and disease[1][3]. For ULK4P2, the classification as a pseudogene indicates it is not itself a tractable molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ULK4 pseudogene 2 (ULK4P2).